{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:40:14Z","timestamp":1789609214173,"version":"build-2803163510"},"reference-count":41,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Thrombocytosis has a large number of potential underlying causes, but the dominant group of hematological conditions for consideration in this setting are the myeloproliferative neoplasms (MPNs). In this chapter, we consider several key linked questions relating to the management of thrombocytosis in MPNs and discuss several issues. First, we discuss the differential diagnosis of thrombocytosis, which myeloid disorders to consider, and practical approaches to the discrimination of each individual MPN from other causes. Second, there have been several major advances in our understanding of the molecular biology of these conditions and we discuss how these findings are likely to be practically applied in the future. Third, we consider whether there is evidence that thrombocytosis contributes to the complications known to be associated with MPN: thrombosis, hemorrhage and transformation to leukemia and myelofibrosis. Last, we review current ideas for risk stratification and management of essential thrombocythemia and polycythemia vera as the 2 entities within the MPN family that are most frequently associated with thrombocytosis.<\/jats:p>","DOI":"10.1182\/asheducation-2014.1.348","type":"journal-article","created":{"date-parts":[[2014,11,24]],"date-time":"2014-11-24T13:39:03Z","timestamp":1416836343000},"page":"348-354","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["Management of MPN beyond JAK2"],"prefix":"10.1182","volume":"2014","author":[{"given":"Claire N.","family":"Harrison","sequence":"first","affiliation":[{"name":"Department of Haematology, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia Curto","family":"Garcia","sequence":"additional","affiliation":[{"name":"Department of Haematology, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"25","key":"2019111703063113400_B1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"issue":"25","key":"2019111703063113400_B2","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111703063113400_B3","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"issue":"10","key":"2019111703063113400_B4","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1038\/leu.2013.74","article-title":"Problems and pitfalls regarding WHO-defined diagnosis of early\/prefibrotic primary myelofibrosis versus essential thrombocythemia","volume":"27","author":"Barbui","year":"2013","journal-title":"Leukemia"},{"issue":"6","key":"2019111703063113400_B5","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1177\/2040620712458947","article-title":"Diagnosis and management of congenital and idiopathic erythrocytosis","volume":"3","author":"McMullin","year":"2012","journal-title":"Ther Adv Hematol"},{"issue":"10","key":"2019111703063113400_B6","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1056\/NEJMc1200349","article-title":"Germline JAK2 mutation in a family with hereditary thrombocytosis","volume":"366","author":"Mead","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111703063113400_B7","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"issue":"7","key":"2019111703063113400_B8","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/leu.2014.57","article-title":"CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"issue":"10","key":"2019111703063113400_B9","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","article-title":"Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia","volume":"123","author":"Rotunno","year":"2014","journal-title":"Blood"},{"issue":"10","key":"2019111703063113400_B10","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/leu.2013.219","article-title":"Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet\/MPN&MPNr-EuroNet (COST action BM0902) study","volume":"27","author":"Jovanovic","year":"2013","journal-title":"Leukemia"},{"issue":"9","key":"2019111703063113400_B11","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/leu.2010.148","article-title":"A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications","volume":"24","author":"Passamonti","year":"2010","journal-title":"Leukemia"},{"issue":"3","key":"2019111703063113400_B12","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1055\/s-0034-1370794","article-title":"Thrombosis in myeloproliferative neoplasms","volume":"40","author":"Falanga","year":"2014","journal-title":"Semin Thromb Hemost"},{"issue":"2","key":"2019111703063113400_B13","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111703063113400_B14","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2012-04-424911","article-title":"Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort","volume":"120","author":"Campbell","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2019111703063113400_B15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111703063113400_B16","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","article-title":"Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial","volume":"121","author":"Gisslinger","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2019111703063113400_B17","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2007-05-091850","article-title":"Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes","volume":"111","author":"Wilkins","year":"2008","journal-title":"Blood"},{"issue":"24","key":"2019111703063113400_B18","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1182\/blood-2013-09-527903","article-title":"Distinct clustering of symptomatic burden amongst myeloproliferative neoplasm patients: retrospective assessment in 1470 patients","volume":"123","author":"Geyer","year":"2014","journal-title":"Blood"},{"issue":"26","key":"2019111703063113400_B19","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"issue":"9","key":"2019111703063113400_B20","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/leu.2010.148","article-title":"A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications","volume":"24","author":"Passamonti","year":"2010","journal-title":"Leukemia"},{"issue":"8","key":"2019111703063113400_B21","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2010-01-263319","article-title":"Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia","volume":"116","author":"Alvarez-Larran","year":"2010","journal-title":"Blood"},{"issue":"8102","key":"2019111703063113400_B22","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0140-6736(78)92098-6","article-title":"Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia","volume":"2","author":"Pearson","year":"1978","journal-title":"Lancet"},{"issue":"2","key":"2019111703063113400_B23","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2141.2006.06430.x","article-title":"The haematocrit and platelet target in polycythemia vera","volume":"136","author":"Di Nisio","year":"2007","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111703063113400_B24","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N Engl J Med"},{"issue":"16","key":"2019111703063113400_B25","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1056\/NEJMc1301262","article-title":"Treatment target in polycythemia vera","volume":"368","author":"McMullin","year":"2013","journal-title":"N Engl J Med"},{"issue":"23","key":"2019111703063113400_B26","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","article-title":"Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project","volume":"121","author":"Barosi","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2019111703063113400_B27","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.leukres.2012.11.004","article-title":"Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS study","volume":"37","author":"Besses","year":"2013","journal-title":"Leuk Res"},{"issue":"10","key":"2019111703063113400_B28","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.3324\/haematol.2011.061390","article-title":"Experience with pegylated interferon alpha-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients","volume":"97","author":"Gowin","year":"2012","journal-title":"Haematologica"},{"issue":"8","key":"2019111703063113400_B29","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/leu.2010.120","article-title":"Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells","volume":"24","author":"Kiladjian","year":"2010","journal-title":"Leukemia"},{"issue":"32","key":"2019111703063113400_B30","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","article-title":"Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera","volume":"27","author":"Quintas-Cardama","year":"2009","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111703063113400_B31","first-page":"4046","article-title":"Efficacy and safety of AOP2014\/P1101, a novel, investigational mono-pegylated proline-interferon alpha-2b, in patients with polycythemia vera (PV): update on 51 patients from the ongoing phase I\/II peginvera study [abstract]","volume":"122","author":"Buxhofer-Ausch","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"1","key":"2019111703063113400_B32","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2141.2010.08430.x","article-title":"Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance\/intolerance to hydroxycarbamide in essential thrombocythaemia","volume":"152","author":"Hernandez-Boluda","year":"2011","journal-title":"Br J Haematol"},{"issue":"22","key":"2019111703063113400_B33","first-page":"753","article-title":"An open-label study of CEP-701 in patients with JAK2 V617F-positive PV and ET: update of 39 enrolled patients [abstract]","volume":"114","author":"Moliterno","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"2019111703063113400_B34","first-page":"313","article-title":"Durable responses with the JAK1\/ JAK2 inhibitor, INCB018424, in patients with polycythemia vera (PV) and essential thrombocythemia (ET) refractory or intolerant to hydroxyurea (HU) [abstract]","volume":"116","author":"Verstovsek","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"4","key":"2019111703063113400_B35","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/cncr.28441","article-title":"A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea","volume":"120","author":"Verstovsek","year":"2014","journal-title":"Cancer"},{"key":"2019111703063113400_B36","doi-asserted-by":"crossref","first-page":"7026","DOI":"10.1200\/jco.2014.32.15_suppl.7026","article-title":"Results of a prospective, randomized, open-label phase 3 study of ruxolitinib (RUX) in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU): the RESPONSE trial [abstract]","volume":"32","author":"Verstovsek S","year":"2014","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111703063113400_B37","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.4065\/mcp.2011.0518","article-title":"Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis","volume":"86","author":"Tefferi","year":"2011","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"2019111703063113400_B38","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/bjh.12416","article-title":"A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia","volume":"162","author":"Andersen","year":"2013","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111703063113400_B39","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/bjh.12332","article-title":"A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy","volume":"161","author":"Finazzi","year":"2013","journal-title":"Br J Haematol"},{"issue":"21","key":"2019111703063113400_B40","first-page":"179","article-title":"Imetelstat rapidly induces and maintains substantial hematologic and molecular responses in patients with essential thrombocythemia (ET) who are refractory or intolerant to prior therapy: preliminary phase II results [abstract]","volume":"120","author":"Baerlocher","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"3","key":"2019111703063113400_B41","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2141.2010.08122.x","article-title":"Guideline for investigation and management of adults and children presenting with a thrombocytosis","volume":"149","author":"Harrison","year":"2010","journal-title":"Br J Haematol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2014\/1\/348\/1250433\/bep00114000348.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2014\/1\/348\/1250433\/bep00114000348.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T03:06:48Z","timestamp":1573960008000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2014\/1\/348\/20484\/Management-of-MPN-beyond-JAK2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,5]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2014.1.348","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,5]]}}}